Current Opinion in Urology:
MALE INCONTINENCE: Edited by Christopher Chapple
Chapple, Christopher R.
Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, UK
Correspondence to Professor Christopher R. Chapple, Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. E-mail: email@example.com
It is a great pleasure to introduce this edition of Current Opinion in Urology dealing with male incontinence. I would like to thank all of the authors for putting together such an interesting series of articles, which deals with the contemporary knowledge base relating to this important problem.
Whilst incontinence in men is relatively uncommon, nevertheless, when it does occur, it has devastating consequences for the patient and this is well recognized. The epidemiology of male incontinence is reviewed in detail by Kari Tikkinen, Arnav Agarwal and Tomas Griebling (pp. 502–508). Clearly it is also essential to make an accurate diagnosis and this is reviewed, looking at the modalities that are available, by Helena Burden, Kate Warren and Paul Abrams (pp. 509–514).
Having considered and identified the clinical symptoms of incontinence and associated features, then appropriate therapy can be instituted. The subject of postprostatectomy incontinence has come to the fore in recent years because of the increasing prevalence of radical prostatectomy and this is discussed by Megan Bing, Matthew Uhlman and Karl Kreder (pp. 540–544).
The remainder of the edition deals with the other therapeutic options that are available, including pharmacotherapy [which is discussed in detail by Konstantinos Giannitsas and Anastasios Athanasopoulos (pp. 515–519)], injectables, balloons and minimally invasive devices [as discussed by Jean-Nicolas Cornu, Laurence Peyrat and François Haab (pp. 536–539)], male slings [as discussed by Nadir Osman (pp. 528–535)], artificial sphincters [reviewed by Bastian Amend, Patricia Toomey and Karl-Dietrich Sievert (pp. 520–527)] and neuromodulation [reviewed by TG Rashid and Jeremy Ockrim (pp. 545–551)].
I hope that you will find these articles useful because certainly they encapsulate the existing body of knowledge relating to the appropriate management of male incontinence.
With best wishes and kind regards,
Conflicts of interest
Speaker for Ranbaxy. Consultant for AMS, Lilly and ONO. Consultant, Researcher, Speaker and Trial Participation for Allergan, Astellas, Pfizer and Recordati.